Welcome!

News Feed Item

Bradmer Announces Fourth Quarter and 2013 Operational and Financial Results

TORONTO, ONTARIO -- (Marketwired) -- 03/07/14 -- Bradmer Pharmaceuticals Inc. ("Bradmer" or the "Company") (TSX VENTURE:BMR.H) today announced its fourth quarter and full year 2013 operational and financial results.

Operational Highlights

On February 19, 2014, the Company announced that it had entered into a letter of intent with Alpha Cancer Technologies Inc. ("Alpha") to complete a going-public transaction for Alpha (the "Proposed Transaction"). Alpha is a pre-clinical biopharmaceutical company with a targeted chemotherapy delivery platform focused on the global oncology market. Alpha holds the exclusive worldwide rights to recombinant human Alpha Fetoprotein (AFP), a shuttle protein that targets AFP receptors found almost exclusively on most solid and liquid cancer cells.

In conjunction with, and prior to the closing of the Proposed Transaction, Alpha intends to complete a private placement of Alpha Shares, 10% convertible notes, subscription receipts and/or other securities convertible into Alpha Shares for aggregate gross proceeds of between $7,000,000 and $10,000,000 (the "Private Placement"), at an offering price or conversion price, as applicable, of $0.50 per Alpha Share. Euro Pacific Canada, Inc. has been engaged by Alpha to act as agent for part of the Private Placement. Any convertible securities of Alpha issued pursuant to the Private Placement will be converted to Alpha Shares immediately prior to the completion of the Amalgamation with Bradmer. The pricing of the Private Placement reflects a pre-money enterprise value for Alpha of approximately $25,000,000.

For the purposes of the Proposed Transaction, the deemed value of each outstanding Bradmer Share will be $0.0632 (on a pre-Amalgamation basis).

Financial Results

Amounts in US dollars, unless specified otherwise, and results prepared in accordance with International Financial Reporting Standards ("IFRS").

For the year ended December 31, 2013, we recorded a net loss of $128,000 or $0.007 per common share based on the weighted average outstanding shares of 19,659,726 during the year, compared to a net loss of $219,000 or $0.011 per common share for the year ended December 31, 2012 based on the weighted average outstanding shares of 19,659,726. The reduced loss in 2013 is attributable to the $52,000 reduction in general and administrative expenses and the $29,000 foreign exchange gain in 2013 compared with the $10,000 foreign exchange loss in 2012.

General and administrative expenses were $157,000 in the year ended December 31, 2013 compared to $209,000 in the prior year.

Major expenses in 2013 consisted of consulting fees of $70,000, legal fees of $26,000, insurance premiums of $19,000, audit fees of $17,000 and transfer agent and stock exchange listing fees of $13,000. Major expenses in 2012 consisted of consulting fees of $72,000, insurance premiums of $57,000, legal fees of $30,000, audit fees of $20,000 and transfer agent and stock exchange listing fees of $19,000. Limits on the directors' and officers' liability insurance were reduced from $5,000,000 to $2,000,000 accounting for the substantial reduction in premiums in 2013.

Fourth Quarter Results

The major reason for the decrease in the loss for the fourth quarter of 2013 to $19,000 from the loss in the third quarter of 2013 of $47,000 was the foreign exchange gain of $12,000 compared to the foreign exchange loss of $7,500 in the previous quarter. General and administrative expenses also declined quarter over quarter from $39,000 to $31,000.

Sources and Uses of Cash

Our operational activities for the year ended December 31, 2013 were financed by cash on hand. At December 31, 2013, we had working capital of $785,000, compared to $971,000 at December 31, 2012. We had available cash of $801,000 at December 31, 2013, compared to cash of $991,000 at December 31, 2012. The decrease was primarily due to the $128,000 operating loss incurred in 2013 and the foreign currency translation adjustments of $59,000.

As at March 7, 2014 and December 31, 2013, the Company had 19,659,726 common shares and options to purchase 1,950,000 common shares outstanding.

Additional information about Bradmer, including the MD&A and financial results may be found on SEDAR at www.sedar.com.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Bradmer's common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this news release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.


BRADMER PHARMACEUTICALS INC.                                                
Statements of Financial Position                                            
As at December 31                                                           
(All amounts expressed in United States dollars)                            
----------------------------------------------------------------------------
----------------------------------------------------------------------------
                                                         2013          2012 
----------------------------------------------------------------------------
                                                                            
Assets                                                                      
                                                                            
Current assets                                                              
  Cash                                           $    800,568  $    990,759 
  Amounts receivable                                    6,668         2,861 
  Prepaid expenses                                      3,079         5,287 
----------------------------------------------------------------------------
                                                                            
Total assets                                     $    810,315  $    998,907 
----------------------------------------------------------------------------
                                                                            
Liabilities and Shareholders' Equity                                        
                                                                            
Current liabilities                                                         
  Accounts payable and accrued liabilities       $     25,665  $     27,440 
----------------------------------------------------------------------------
                                                                            
Shareholders' Equity                                                        
  Share capital                                     2,158,896     2,307,972 
  Contributed surplus                               2,385,647     2,550,381 
  Accumulated other comprehensive income/(loss)        98,604      (156,515)
  Deficit                                          (3,858,497)   (3,730,371)
----------------------------------------------------------------------------
                                                                            
Total shareholders' equity                            784,650       971,467 
----------------------------------------------------------------------------
Total liabilities and shareholders' equity       $    810,315  $    998,907 
                                                                            
BRADMER PHARMACEUTICALS INC.                                                
Statements of Comprehensive Income/(Loss)                                   
For the years ended December 31, 2013 and 2012                              
(All amounts expressed in United States dollars)                            
----------------------------------------------------------------------------
----------------------------------------------------------------------------
                                                                            
                                                          2013         2012 
----------------------------------------------------------------------------
                                                                            
Expenses                                                                    
  General and administrative                       $   157,163  $   209,375 
----------------------------------------------------------------------------
                                                                            
Other Income                                                                
  Interest                                                (203)        (390)
  Foreign exchange (gain)/loss                         (28,834)       9,765 
----------------------------------------------------------------------------
                                                                            
                                                       (29,037)       9,375 
----------------------------------------------------------------------------
                                                                            
Loss for the year                                  $  (128,126) $  (218,750)
                                                                            
Other comprehensive income/(loss)                      255,119      (80,717)
----------------------------------------------------------------------------
                                                                            
Comprehensive income/(loss) for the year           $   126,993  $  (299,467)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
                                                                            
Loss per share                                                              
Basic and diluted                                  $    (0.007) $    (0.011)
----------------------------------------------------------------------------
                                                                            
Weighted average number of shares outstanding       19,659,726   19,659,726 
----------------------------------------------------------------------------
                                                                            
BRADMER PHARMACEUTICALS INC.                                                
Statements of Changes in Shareholders' Equity                               
For the years ended December 31, 2013 and 2012                              
(All amounts expressed in United States dollars)                            
----------------------------------------------------------------------------
----------------------------------------------------------------------------
                                                                            
                          Share capital                                     
                          Number                                Contributed 
                       of shares        Amount       Warrants       surplus 
----------------------------------------------------------------------------
                                                                            
Balance, January                                                            
 1, 2012              19,659,726  $  2,257,819  $      23,255  $  2,471,705 
                                                                            
Expiry of                                                                   
 warrants                      -             -        (23,255)       23,255 
                                                                            
Foreign currency                                                            
 translation                                                                
 adjustment                    -        50,153              -        55,421 
                                                                            
Loss for the year              -             -              -             - 
----------------------------------------------------------------------------
                                                                            
Balance, December                                                           
 31, 2012             19,659,726  $  2,307,972  $           -  $  2,550,381 
                                                                            
Foreign currency                                                            
 translation                                                                
 adjustment                    -      (149,076)             -      (164,734)
                                                                            
Loss for the year              -             -              -             - 
----------------------------------------------------------------------------
                                                                            
Balance, December                                                           
 31, 2013             19,659,726  $  2,158,896  $           -  $  2,385,647 
----------------------------------------------------------------------------
----------------------------------------------------------------------------

                                                              
                     Accumulated                              
                           Other                        Total 
                   Comprehensive                Shareholders' 
                  Income/ (Loss)       Deficit         equity 
--------------------------------------------------------------
                                                              
Balance, January                                              
 1, 2012          $      (75,798) $ (3,511,621) $   1,165,360 
                                                              
Expiry of                                                     
 warrants                      -             -              - 
                                                              
Foreign currency                                              
 translation                                                  
 adjustment              (80,717)            -         24,857 
                                                              
Loss for the year              -      (218,750)      (218,750)
--------------------------------------------------------------
                                                              
Balance, December                                             
 31, 2012         $     (156,515) $ (3,730,371) $     971,467 
                                                              
Foreign currency                                              
 translation                                                  
 adjustment              255,119             -        (58,691)
                                                              
Loss for the year              -      (128,126)      (128,126)
--------------------------------------------------------------
                                                              
Balance, December                                             
 31, 2013         $       98,604  $ (3,858,497) $     784,650 
--------------------------------------------------------------
--------------------------------------------------------------
                                                                            
BRADMER PHARMACEUTICALS INC.                                                
Statements of Cash Flows                                                    
For the years ended December 31, 2013 and 2012                              
(All amounts expressed in United States dollars)                            
----------------------------------------------------------------------------
----------------------------------------------------------------------------
                                                                            
                                                          2013         2012 
----------------------------------------------------------------------------
                                                                            
Cash flows from operating activities                                        
  Loss for the year                                $  (128,126) $  (218,750)
  Adjustments for:                                                          
    Foreign currency translation adjustment            (58,691)      24,857 
----------------------------------------------------------------------------
                                                                            
                                                      (186,817)    (193,893)
  Change in non-cash operating items                                        
    Amounts receivable                                  (3,807)          90 
    Prepaid expenses                                     2,208        2,266 
    Accounts payable and accrued expenses               (1,775)     (10,011)
----------------------------------------------------------------------------
                                                                            
Decrease in cash                                      (190,191)    (201,548)
                                                                            
Cash at beginning of year                              990,759    1,192,307 
----------------------------------------------------------------------------
                                                                            
Cash at end of year                                $   800,568  $   990,759 
----------------------------------------------------------------------------

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
The essence of cloud computing is that all consumable IT resources are delivered as services. In his session at 15th Cloud Expo, Yung Chou, Technology Evangelist at Microsoft, demonstrated the concepts and implementations of two important cloud computing deliveries: Infrastructure as a Service (IaaS) and Platform as a Service (PaaS). He discussed from business and technical viewpoints what exactly they are, why we care, how they are different and in what ways, and the strategies for IT to transi...
Culture is the most important ingredient of DevOps. The challenge for most organizations is defining and communicating a vision of beneficial DevOps culture for their organizations, and then facilitating the changes needed to achieve that. Often this comes down to an ability to provide true leadership. As a CIO, are your direct reports IT managers or are they IT leaders? The hard truth is that many IT managers have risen through the ranks based on their technical skills, not their leadership abi...
Interoute has announced the integration of its Global Cloud Infrastructure platform with Rancher Labs’ container management platform, Rancher. This approach enables enterprises to accelerate their digital transformation and infrastructure investments. Matthew Finnie, Interoute CTO commented “Enterprises developing and building apps in the cloud and those on a path to Digital Transformation need Digital ICT Infrastructure that allows them to build, test and deploy faster than ever before. The int...
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service.
Niagara Networks exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
SYS-CON Events announced today that Outlyer, a monitoring service for DevOps and operations teams, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Outlyer is a monitoring service for DevOps and Operations teams running Cloud, SaaS, Microservices and IoT deployments. Designed for today's dynamic environments that need beyond cloud-scale monitoring, we make monitoring effortless so you ...
Virtualization over the past years has become a key strategy for IT to acquire multi-tenancy, increase utilization, develop elasticity and improve security. And virtual machines (VMs) are quickly becoming a main vehicle for developing and deploying applications. The introduction of containers seems to be bringing another and perhaps overlapped solution for achieving the same above-mentioned benefits. Are a container and a virtual machine fundamentally the same or different? And how? Is one techn...
My team embarked on building a data lake for our sales and marketing data to better understand customer journeys. This required building a hybrid data pipeline to connect our cloud CRM with the new Hadoop Data Lake. One challenge is that IT was not in a position to provide support until we proved value and marketing did not have the experience, so we embarked on the journey ourselves within the product marketing team for our line of business within Progress. In his session at @BigDataExpo, Sum...
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, will discuss the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information,
China Unicom exhibit at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. China United Network Communications Group Co. Ltd ("China Unicom") was officially established in 2009 on the basis of the merger of former China Netcom and former China Unicom. China Unicom mainly operates a full range of telecommunications services including mobile broadband (GSM, WCDMA, LTE FDD, TD-LTE), fixed-line broadband, ICT, data communica...
With the introduction of IoT and Smart Living in every aspect of our lives, one question has become relevant: What are the security implications? To answer this, first we have to look and explore the security models of the technologies that IoT is founded upon. In his session at @ThingsExpo, Nevi Kaja, a Research Engineer at Ford Motor Company, will discuss some of the security challenges of the IoT infrastructure and relate how these aspects impact Smart Living. The material will be delivered i...
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, schedulers and micro services. While we have figured out how to run containerized applications in the cloud using schedulers, we've yet to come up with a good solution to bridge the gap between getting your contain...